Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.650-0.700 for the period, compared to the consensus estimate of 0.710. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $2.9 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on AMRX shares. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $9.00 to $12.00 in a report on Monday, February 24th. Finally, Piper Sandler lifted their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $10.60.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX opened at $8.67 on Friday. Amneal Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $9.48. The company has a 50-day moving average of $8.10 and a 200 day moving average of $8.32. The firm has a market cap of $2.69 billion, a PE ratio of -12.75 and a beta of 1.10.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The firm had revenue of $730.52 million for the quarter, compared to analysts’ expectations of $708.21 million. During the same period in the previous year, the company posted $0.14 earnings per share. Sell-side analysts anticipate that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Insider Activity

In other news, Director Gautam Patel sold 62,590 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total transaction of $501,345.90. Following the transaction, the director now owns 1,968,886 shares in the company, valued at $15,770,776.86. This represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 160,000 shares of company stock worth $1,292,000 over the last 90 days. 26.56% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.